Corporate Risk Management
Santhera Pharmaceuticals' Single-Asset Bet: How Vamorolone Dependency Shapes the Company's Financial Fate
ViaNews Editorial Team (Finance)•
#Duchenne Muscular Dystrophy
2 articles
Biotech & Pharmaceuticals
REGENXBIO Eyes 2027 Commercial Launch for Duchenne Gene Therapy as Pivotal Trial Wraps Enrollment
ViaNews Editorial Team (Finance)•